scholarly journals Incidence of clinically suspected venous thromboembolism in British Indian patients

2018 ◽  
Vol 100 (5) ◽  
pp. 413-416 ◽  
Author(s):  
BM Siddiqui ◽  
MS Patel ◽  
S Rudge ◽  
A Best ◽  
J Mangwani
Keyword(s):  
Public Health ◽  
Venous Thromboembolism ◽  
Public Health Issue ◽  
Major Public Health Issue ◽  
Vein Thrombosis ◽  
Indian Patients ◽  
Significant Difference ◽  
The World ◽  
The Uk ◽  
Deep Vein

Introduction Venous thromboembolism (VTE) remains a major public health issue around the world. Ethnicity is known to alter the incidence of VTE. To our knowledge, there are no reports in the literature investigating the incidence of VTE in British Indians. The aim of this study was to investigate the rates of symptomatic VTE in British Indian patients in the UK. Methods Patients referred to our institution between January 2011 and August 2013 with clinically suspected VTE were eligible for inclusion in the study. Those not of British Indian or Caucasian ethnicity were excluded. A retrospective review of these two cohorts was conducted. Results Overall, 15,529 cases were referred to our institution for suspected VTE. This included 1,498 individuals of British Indian ethnicity. Of these, 182 (12%) had confirmed VTE episodes. A further 13,159 of the patients with suspected VTE were coded as Caucasian, including 2,412 (16%) who had confirmed VTE events. VTE rates were a third lower in British Indians with clinically suspected VTE than in the equivalent Caucasian group. The British Indian cohort presented with VTE at a much earlier age than Caucasians (mean 57.0 vs 68.0 years). Conclusions This study suggests that British Indian patients have a lower incidence of VTE and are more likely to present at an earlier age than Caucasians. There was no significant difference in VTE type (deep vein thrombosis vs pulmonary embolism) among the ethnic groups. Clinicians should be aware of variations within ethnicities but should continue to adhere to existing VTE prevention guidance.

scholarly journals Epidemiological analysis of strokes in Grande Vitória, Espírito Santo

2021 ◽  
Author(s):  
Catharina Mello Barreto ◽  
Amanda Ferraz Arita ◽  
Ana Carolina Coutinho Engelhardt Bravin ◽  
Julia Surrage da Matta ◽  
Maria de Fatima Araujo da Fonseca ◽  
...  
Keyword(s):  
Public Health ◽  
Mortality Rate ◽  
Ecological Study ◽  
Cerebrovascular Diseases ◽  
Public Health Issue ◽  
Major Public Health Issue ◽  
Epidemiological Analysis ◽  
Espírito Santo ◽  
The World ◽  
Espirito Santo

Introduction: Stroke is a neurological syndrome resulting from a vascular injury that represents one of the main causes of morbidity and mortality in the world. Thus, cerebrovascular diseases are increasing in Brazilian statistics, especially the ischemic stroke, responsible for the highest incidence in cases, therefore characterizing a major public health issue. Methods: In this descriptive and ecological study we used data provided by DATASUS concerning hospitalizations and deaths due to stroke, not specified as hemorrhagic or ischemic, occurred between January 2008 and December 2020 in the region of Grande Vitória, Espírito Santo (GV – ES). Results: Overall, there were 10,199 hospitalizations due to stroke in the GV-ES. The prevalence was 57.2% in brown-skinned people, 26.2% between ages from 60 to 69 years old (26.2%) and 52% in Vitória. Among 2008 until 2014 there was an increase of 788.9% in stroke hospitalizations however between 2015 and 2020 there was a 30.5% reduction. In total there were 1,309 deaths, 64% were brown-skinned people, 29.2% above 80 years old and 51.3% in Vitoria. From 2008 to 2019, a 144.5% increase in the mortality rate was observed. In the analyzes there was no difference regarding the gender. Conclusion: Data analysis inferred that old age and brown skin are risk factors for stroke in GV-ES, thereby requiring greater attention for screening and preventing this disease in those groups. Moreover, there was an increase in the mortality rate, even with reduction in the number of cases, reinforcing the need for effective and resolute care in the region.

Hereditary Thrombophilic Risk Factors and Venous Thromboembolism in Istanbul, Turkey: The Role in Different Clinical Manifestations of Venous Thromboembolism

2008 ◽  
Vol 14 (2) ◽  
pp. 168-173 ◽  
Author(s):  
Gulfer Okumus ◽  
Esen Kiyan ◽  
Orhan Arseven ◽  
Levent Tabak ◽  
Reyhan Diz-Kucukkaya ◽  
...  
Keyword(s):  
Risk Factors ◽  
Venous Thromboembolism ◽  
Clinical Manifestations ◽  
Factor V Leiden ◽  
Protein S ◽  
Prothrombin G20210a ◽  
Factor V ◽  
Vein Thrombosis ◽  
Significant Difference ◽  
Deep Vein

The aim of this study was to investigate the hereditary thrombophilic risk factors in patients with venous thromboembolism (VTE) and whether these risk factors play a different role in patients with isolated pulmonary embolism (PE) as compared with patients with deep vein thrombosis (DVT) and patients with PE + DVT. The protein C (PC), protein S, antithrombin activities, homocysteine levels, and factor V Leiden (FVL) G1691A and prothrombin G20210A mutations were evaluated in 191 patients with VTE and 191 controls. The prevalence of FVL and PC deficiency were higher in patients ( P = .003 and P = .02, respectively). There was no significant difference for the other risk factors. The combination of thrombophilic risk factors was significantly higher in patients with DVT + PE as compared with patients with isolated PE or DVT ( P = .04). In conclusion, the most important hereditary risk factors for VTE in this study were the FVL mutation and PC deficiency.

scholarly journals Venous Thromboembolism in Patents With Lung Cancer

2020 ◽  
Vol 26 ◽  
pp. 107602962097791
Author(s):  
Takahito Suzuki ◽  
Susumu Fujino ◽  
Shouta Inaba ◽  
Ryo Yamamura ◽  
Hiromasa Katoh ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Deep Vein Thrombosis ◽  
Venous Thromboembolism ◽  
Cancer Patients ◽  
Cause Of Death ◽  
Clinicopathological Characteristics ◽  
Lung Cancer Patients ◽  
Vein Thrombosis ◽  
Significant Difference ◽  
Deep Vein

Lung cancer is the leading cause of death from cancer in Japan. Studies in other countries have reported a venous thromboembolism (VTE) rate of 4%–20% in cancer patients. In this study, we aimed to determine the incidence of VTE in lung cancer patients in Japan and compared the characteristics of patients with and without VTE. In this retrospective cohort study, the clinicopathological characteristics of study patients with and without concomitant VTE were compared. Patients with lung cancer treated at Fukui Prefectural Hospital, Japan from 2008 to 2017. Of the 1471 patients with lung cancer studied, 28 developed VTE. Five patients developed pulmonary thromboembolism (PTE) alone, 9 PTE with concomitant deep vein thrombosis, and 14 deep vein thrombosis alone. Compared with patients in the non-VTE group, the VTE group was significantly younger (mean value ± SD 66.3 ± 10.1 vs. 73.0 ± 10.6 years, p = 0.001), contained significantly more patients with stage IIIb–IV disease (p = 0.002), and had a significantly higher rate of chemotherapy (p < 0.001) and radiation therapy (p = 0.007). There was no significant difference in median survival time from lung cancer diagnosis between the VTE and non-VTE groups. The 1-year mortality rate after VTE diagnosis was 60.7%. Lung cancer was the most frequent cause of death, followed by infection and VTE. Several baseline characteristics differed between patients with and without VTE. The prognosis may worsen after development of VTE, suggesting that lung cancer patients should be carefully monitored for it.

scholarly journals Immunochromatographic Technique for Seropositivity and PCR Based Molecular Diagnosis for Hepatis B and C Virus in a General Population of Mansehra Pakistan

2020 ◽  
Keyword(s):  
Public Health ◽  
General Population ◽  
Viral Infections ◽  
Public Health Issue ◽  
Major Public Health Issue ◽  
Blood Samples ◽  
The World ◽  
Awareness Programs ◽  
Pcr Method ◽  
Day By Day

Hepatitis B and C infections are known to be the major public health issue around the world. Our focus is to investigate the predominance of HBV and HCV infections in the general population of district Mansehra, Khyber Pakhtunkhwa, Pakistan. Blood samples were taken from 652 individuals and were shifted to Alkhedmat laboratory Mansehra and Department of Microbiology Hazara University Mansehra. Serum were isolated from blood samples and screen it by ICT device Kit (Accurate Diagnostics, Houston, Texas, USA). The ICT positive samples were then refined by PCR method. Total 652 individuals [males (368), females (284)] were screened for HBV and HCV infections in which total 37 (5.67%) [males (6.52%) and females (4.57%)] were found positive for HBsAg and 42 (6.44%) [males (7.33%) and females (5.28%)] were found positive for Anti HCV respectively. The ratio of these viral infections is more predominant as compare to other viral infections in Mansehra, Pakistan. The rate of HBV and HCV prevalence is increasing day by day in these areas. Communities with more than 5% HBV and HCV disease, mass vaccination and awareness programs should be undertaken as a matter of urgency.

scholarly journals Venous Thromboembolism Within Professional American Sport Leagues

2017 ◽  
Vol 5 (12) ◽  
pp. 232596711774553 ◽  
Author(s):  
Meghan Bishop ◽  
Matthew Astolfi ◽  
Eric Padegimas ◽  
Peter DeLuca ◽  
Sommer Hammoud
Keyword(s):  
Pulmonary Embolism ◽  
Deep Vein Thrombosis ◽  
Venous Thromboembolism ◽  
Lower Extremity ◽  
Upper Extremity ◽  
Return To Play ◽  
Professional Athletes ◽  
Vein Thrombosis ◽  
Significant Difference ◽  
Deep Vein

Background: Numerous reports have described players in professional American sports leagues who have been sidelined with a deep vein thrombosis (DVT) or a pulmonary embolism (PE), but little is known about the clinical implications of these events in professional athletes. Purpose: To conduct a retrospective review of injury reports from the National Hockey League (NHL), Major League Baseball (MLB), the National Basketball Association (NBA), and the National Football League (NFL) to take a closer look at the incidence of DVT/PE, current treatment approaches, and estimated time to return to play in professional athletes. Study Design: Descriptive epidemiology study. Methods: An online search of all team injury and media reports of DVT/PE in NHL, MLB, NBA, and NFL players available for public record was conducted by use of Google, PubMed, and SPORTDiscus. Searches were conducted using the professional team name combined with blood clot, pulmonary embolism, and deep vein thrombosis. Results: A total of 55 venous thromboembolism (VTE) events were identified from 1999 through 2016 (NHL, n = 22; MLB, n = 16; NFL, n = 12; NBA, n = 5). Nineteen athletes were reported to have an upper extremity DVT, 15 had a lower extremity DVT, 15 had a PE, and 6 had DVT with PE. Six athletes sustained more than 1 VTE. The mean age at time of VTE was 29.3 years (range, 19-42 years). Mean (±SD) time lost from play was 6.7 ± 4.9 months (range, 3 days to career end). Seven athletes did not return to play. Players with upper extremity DVT had a faster return to play (mean ± SD, 4.3 ± 2.7 months) than those with lower extremity DVT (5.9 ± 3.8 months), PE (10.8 ± 6.8 months), or DVT with PE (8.2 ± 2.6 months) ( F = 5.69, P = .002). No significant difference was found regarding time of return to play between sports. Conclusion: VTE in professional athletes led to an average of 6.7 months lost from play. The majority of athletes were able to return to play after a period of anticoagulation or surgery. Those with an upper extremity DVT returned to play faster than those with other types of VTE. Further study is needed to look into modifiable risk factors for these events and to establish treatment and return-to-play guidelines to ensure the safety of these athletes.

Neuromuscular electrical stimulation for the prevention of venous thromboembolism

2017 ◽  
Vol 33 (6) ◽  
pp. 367-378 ◽  
Author(s):  
Raveena Ravikumar ◽  
Katherine J Williams ◽  
Adarsh Babber ◽  
Hayley M Moore ◽  
Tristan RA Lane ◽  
...  
Keyword(s):  
Electrical Stimulation ◽  
Deep Vein Thrombosis ◽  
Venous Thromboembolism ◽  
Confidence Interval ◽  
Odds Ratio ◽  
Neuromuscular Electrical Stimulation ◽  
Venous Stasis ◽  
Vein Thrombosis ◽  
Significant Difference ◽  
Deep Vein

Objective Venous thromboembolism, encompassing deep vein thrombosis and pulmonary embolism, is a significant cause of morbidity and mortality, affecting one in 1000 adults per year. Neuromuscular electrical stimulation is the transcutaneous application of electrical impulses to elicit muscle contraction, preventing venous stasis. This review aims to investigate the evidence underlying the use of neuromuscular electrical stimulation in thromboprophylaxis. Methods The Medline and Embase databases were systematically searched, adhering to PRISMA guidelines, for articles relating to electrical stimulation and thromboprophylaxis. Articles were screened according to a priori inclusion and exclusion criteria. Results The search strategy identified 10 randomised controlled trials, which were used in three separate meta-analyses: five trials compared neuromuscular electrical stimulation to control, favouring neuromuscular electrical stimulation (odds ratio of deep vein thrombosis 0.29, 95% confidence interval 0.13–0.65; P = .003); three trials compared neuromuscular electrical stimulation to heparin, favouring heparin (odds ratio of deep vein thrombosis 2.00, 95% confidence interval 1.13–3.52; P = .02); three trials compared neuromuscular electrical stimulation as an adjunct to heparin versus heparin only, demonstrating no significant difference (odds ratio of deep vein thrombosis 0.33, 95% confidence interval 0.10–1.14; P = .08). Conclusion Neuromuscular electrical stimulation significantly reduces the risk of deep vein thrombosis compared to no prophylaxis. It is inferior to heparin in preventing deep vein thrombosis and there is no evidence for its use as an adjunct to heparin.

An Enzyme Immunoassay (ELISA) for the Quantitation of Human Factor VII

1986 ◽  
Vol 56 (03) ◽  
pp. 250-255 ◽  
Author(s):  
C Boyer ◽  
M Wolf ◽  
C Rothschild ◽  
M Migaud ◽  
J Amiral ◽  
...  
Keyword(s):  
Human Factor ◽  
Solid Phase ◽  
Factor Vii ◽  
Enzyme Linked Immunosorbent Assay ◽  
Poor Correlation ◽  
Vein Thrombosis ◽  
Coagulant Activity ◽  
Significant Difference ◽  
Large Populations ◽  
Deep Vein

SummaryA new solid phase enzyme-linked immunosorbent assay (ELISA) was developed for the quantitation of human Factor VII antigen (F VII Ag), using a monospecific rabbit anti-F VII antiserum. Anti-F VII F(ab′)2 fragments were adsorbed to polystyrene plates. The binding of serial dilutions of control or test plasma, containing F VII, was detected by incubation with peroxidase-labeled anti- FV II IgG followed by the addition of hydrogen peroxyde and O-phenylenediamine. This ELISA is specific, sensitive (detection limit: 0.05%) and accurate (coefficient of variation: 1.5-4% for within- and 1.6-9% for between-assays). F VII coagulant activity (F VII C) and F VII Ag were determined in large populations of controls and patients. In normal plasma (n = 38), F VII Ag ranged from 83 to 117% and the correlation coefficient between F VII Ag and F VII C was 0.94. In patients with severe (F VII C inf. 1%) congenital F VII deficiency (n = 5), F VII Ag was undetectable in two cases (inf. 0.05%) and markedly reduced (0.35 to 5.6%) in the three other cases. In patients with liver cirrhosis (n = 15), F VII Ag ranged from 21 to 59% and was in good correlation with F VII C (r = 0.84). In dicoumarol treated patients (n = 15), the levels of F VII Ag ranged from 51% to 79% and a poor correlation (r = 0.52) with F VIIC was observed. In “compensated” DIC (n = 5), levels of F VII Ag varied from 60 to 186%, with significantly higher F VII C levels (from 143 to 189%). In contrast, in “decompensated” DIC (n = 7), low F VII Ag and F VII C levels were observed (from 7 to 27%). In patients with deep-vein thrombosis (n = 25), high levels of F VII Ag (from 102 to 136%) and F VII C (from 110 to 150%) were demonstrated. In surgical patients, no significant difference was observed before and one day after intervention.

scholarly journals Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort Study

2021 ◽  
Vol 27 ◽  
pp. 107602962097957
Author(s):  
Soo-Mee Bang ◽  
Jin-Hyoung Kang ◽  
Min Hee Hong ◽  
Jin-Seok Ahn ◽  
So Yeon Oh ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Cancer Patients ◽  
Clinical Outcomes ◽  
Oral Anticoagulants ◽  
Direct Oral Anticoagulants ◽  
Bleeding Events ◽  
Factors Associated ◽  
Vein Thrombosis ◽  
Medical Chart Review ◽  
Deep Vein

This study assessed epidemiologic data and clinical outcomes, including venous thromboembolism (VTE) recurrence and bleeding events, in patients with cancer-associated VTE, and assessed factors associated with clinical outcomes. Data were extracted from retrospective medical-chart review of adult patients diagnosed with cancer-associated deep vein thrombosis or pulmonary embolism who received anticoagulation treatment for ≥3 months. Patients were classified by: low-molecular-weight heparin (LMWH), direct oral anticoagulants (DOACs), and other anticoagulants. First VTE recurrence and bleeding events, and factors associated with their occurrence, were assessed during the initial 6 months of treatment. Overall, 623 patients (age: 63.7 ± 11.3 years, 49.3% male) were included (119, 132, and 372 patients in LMWH, DOACs and other anticoagulants groups, respectively). The cumulative 6-month incidence of VTE recurrence was 16.6% (total), 8.3% (LMWH), 16.7% (DOACs), and 20.7% (other); respective bleeding events were 22.5%, 11.0%, 12.3%, and 30.7%). VTE recurrence and bleeding rates differed only between LMWH and other anticoagulants (HR 2.4, 95% CI: 1.2-5.0 and 3.6, 1.9-6.8, respectively). These results highlight the importance of initial VTE treatment choice for preventing VTE recurrence and bleeding events. LMWH or DOACs for ≥3 months can be considered for effective VTE management in cancer patients.

Sign in / Sign up

Export Citation Format

Share Document